TLPPF Stock Chart & Stats
$11.52
-$0.46(-4.37%)
At close: 4:00 PM EDT
$11.52
-$0.46(-4.37%)
Day’s Range― - ―
52-Week Range$5.91 - $13.00
Previous CloseN/A
Volume1.10K
Average Volume (3M)2.82K
Market Cap
$3.47B
Enterprise Value$6.39B
Total Cash (Recent Filing)$363.61M
Total Debt (Recent Filing)$836.98M
Price to Earnings (P/E)98.2
Beta1.35
Next Earnings
Feb 19, 2027EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding340,330,380
10 Day Avg. Volume320
30 Day Avg. Volume2,821
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue4.88
Enterprise Value/Gross Profit9.35
Enterprise Value/Ebitda141.44
Forecast
1Y Price Target
$17.72Price Target Upside53.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.05
Revenue Forecast (FY)$688.49M
Bulls Say, Bears Say
Bulls Say
Strong Commercial GrowthSustained double-digit growth across the group and core Precision Medicine franchise indicates expanding commercial adoption rather than reliance on a single temporary gain. Continued growth at this scale can strengthen operating leverage, support pipeline investment, and broaden Telix’s revenue base over the next several quarters.
Healthy And Improving MarginsImproving gross margins alongside disciplined operating expenses points to better product economics and operating leverage as revenue scales. This supports more durable profitability potential, gives management greater capacity to fund development internally, and reduces the amount of incremental revenue needed to support future earnings.
Broader Platform And InfrastructureAdding an approved product in neuro-oncology while pursuing a vertically integrated ITM combination could diversify revenue and expand therapeutic reach. Broader isotope production, manufacturing, and pipeline capabilities may improve Telix’s ability to serve patients at scale and support multiple future launches.
Bears Say
Recent Cash-flow ReversalThe reversal into negative operating and free cash flow weakens cash conversion and increases reliance on financing while the company continues investing in growth. If sustained, it could constrain reinvestment flexibility and make execution more sensitive to spending levels, working capital needs, and product timing.
Rising LeverageDebt growing faster than the equity base reduces financial flexibility for a business with volatile earnings and substantial development investment. Elevated leverage can increase interest and refinancing exposure, limit capacity for additional strategic spending, and amplify the consequences if profitability softens.
Zircaix Regulatory HurdleThe FDA response delays potential commercialization of an important pipeline asset and leaves approval timing dependent on addressing identified manufacturing deficiencies. A prolonged resubmission process could defer revenue diversification, increase regulatory execution costs, and keep future growth dependent on existing products.
Telix Pharmaceuticals News
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $5.91 and its highest was $13.00 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $3.47B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2027 which is in 119 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.15.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 340,330,380 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $0.17 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 1.431%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.72 (53.79% Upside)
$17.72 (53.79% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 97%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $133.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
7.11%
Trailing 12-Months
Asset Growth
14.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLPPF Company Deck
TLPPF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.View all TLPPF earnings summariesTLPPF Stock 12 Month Forecast
Average Price Target
$17.72
▲(53.79% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Ownership Overview
6.30% Insiders
0.86% Mutual Funds
― Other Institutional Investors
88.28% Public Companies and
Individual Investors